Abstract
Interferon-α (IFNα) was the first effective drug therapy for hairy cell leukemia (HCL). Nowadays, it is used as an alternative treatment in selected patients. Due to unlimited treatment time, monitoring and early prediction of response are important. Moreover, IFNα is used in the therapy of chronic hepatitis C, where a single nucleotide polymorphism of interleukin-28B gene (IL28B) correlates with therapy response. The role of this polymorphism in therapy response of IFNα-treated patients with HCL is unknown. Thirty-seven HCL patients treated between 1978 and 2014 were included in this study. Treatment strategy and response parameters (blood cell counts, soluble interleukin-2 receptor (sIL2R), and bone marrow examination) have been assessed. Relative decrease of sIL2R was correlated with outcome parameters. Response parameters of IFNα-treated patients were correlated with IL28B polymorphism. Twenty-one patients were analyzed for the correlation of sIL2R ratio and outcome. After 1 and 3 months of therapy (IFNα or cladribine (CDA)), the median sIL2R level showed a relative decrease of 79 and 91%. These decreases significantly correlate with time to complete remission (CR, p = 0.029 and p = 0.018). Correlation analyses of IL28B genotype with outcome parameters are not significant. Six patients (16%) were diagnosed with secondary malignancies, and one death was registered (median follow-up time 14 years). IFNα is a safe, effective, and well-tolerated long-term treatment in HCL. Relative decreases of sIL2R levels correlate with time to CR and are useful as early predictor for response. There is no significant correlation between IL28B polymorphism and treatment response to IFNα.
Similar content being viewed by others
References
Campo E, Swerdlow SH, Harris NL et al (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 19:5019–5032
Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood 13:609–630
Smith A, Howell D, Patmore R et al (2011) Incidence of haematological malignancy by sub-type: a report from the haematological malignancy research network. Br J Cancer 105:1684–1692
Grever MR (2010) How I treat hairy cell leukemia. Blood 115:21–28
Bouroncle BA (1979) Leukemic reticuloendotheliosis (hairy cell leukemia). Blood 53:412–436
Jones G, Parry-Jones N, Wilkins B et al (2012) Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol 156:186–195
Arcaini L, Zibellini S, Boveri E et al (2012) The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 119:188–191
Chandran R, Gardiner SK, Smith SD et al (2013) Improved survival in hairy cell leukaemia over three decades: a SEER database analysis of prognostic factors. Br J Haematol 163:407–409
Grever M, Kopecky K, Foucar MK et al (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13:974–982
Maevis V, Mey U, Schmidt-Wolf G et al (2014) Hairy cell leukemia: short review, today's recommendations and outlook. Blood Cancer J 4:e184
Robak T, Matutes E, Catovsky D et al (2015) Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v100–v107
Dietrich S, Pircher A, Endris V et al (2016) BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 127:2847–2855
Kreitman RJ, Tallman MS, Robak T et al (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30:1822–1828
Nyalakonda H, Utay NS (2015) A new era of therapy for hepatitis C virus infection. Curr Opin Infect Dis
Fried MW, Shiffman ML, Reddy KR et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982
Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399–401
Lauria F, Rondelli D, Raspadori D et al (1992) Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment. Leuk Lymphoma 7:103–107
Richards JM, Mick R, Latta JM et al (1990) Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. Blood 76:1941–1945
Benz R, Siciliano RD, Stussi G et al (2009) Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia. Eur J Haematol 82:194–200
(2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama ;310:2191–2194
USZ (2014) Laktat Dehydrogenase (LDH). UniversitätsSpital Zürich, Zürich
Else M, Dearden CE, Matutes E et al (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 145:733–740
Common Terminology Criteria for Adverse Events (CTCAE) (2009) U.S.Departement of health and human services. National Cancer Institute, USA
Golomb HM, Catovsky D, Golde DW (1978) Hairy cell leukemia: a clinical review based on 71 cases. Ann Intern Med 89:677–683
Somasundaram V, Purohit A, Aggarwal M et al (2014) Hairy cell leukemia: a decade long experience of north Indian hematology center. Indian J Med Paediatr Oncol 35:271–275
Bouafia F, Drai J, Bienvenu J et al (2004) Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies. Bull Cancer 91:E229–E240
Mhawech-Fauceglia P, Oberholzer M, Aschenafi S et al (2006) Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 130:374–377
Sharafi H, Pouryasin A, Alavian SM et al (2012) Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals. Hepat Mon 12:e8387
Gelinas JF, Fabre T, Willems P et al (2013) IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics 65:397–403
Hisada M, Chen BE, Jaffe ES et al (2007) Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. J Natl Cancer Inst 99:215–222
Federico M, Zinzani PL, Frassoldati A et al (2002) Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol 20:638–646
Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V et al (2015) Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood 126:1762–1769
Jain P, Pemmaraju N, Ravandi F (2014) Update on the biology and treatment options for hairy cell leukemia. Curr Treat Options in Oncol 15:187–209
Authors’ contributions
SJ, RB, and JSG designed the study, acquisitated, and analyzed data and wrote the paper. KS performed the blood analysis. OS reviewed the data and supported the statistical analysis and interpretation. All the authors critically reviewed the article and gave final approval.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that they have no conflict of interest.
Electronic supplementary material
ESM 1
(DOCX 144 kb)
Rights and permissions
About this article
Cite this article
Jud, S., Goede, J.S., Senn, O. et al. sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-α therapy. Ann Hematol 96, 757–763 (2017). https://doi.org/10.1007/s00277-017-2943-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-017-2943-8